Zoetis Inc (ZTS)
Healthcare
Drug Manufacturers - Specialty & Generic
77.30 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Zoetis Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Aktien.Guide
Dividends
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
32.6$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
419Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.8%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.7
Performance
Perf. 1M
Price performance over the last month.
-6.40%
Perf. 3M
Price performance over the last 3 months.
-35.10%
Perf. 6M
Price performance over the last 6 months.
-41.10%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-38.40%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-51.9%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
12.5
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
10.9
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
1.8
P/B
Price-to-book ratio: market value relative to book equity.
9.9
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
3.4
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
9.5
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
15.3
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
71.8%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
36.6%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
28.0%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
67.8%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
15.5%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
21.3%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
20.3
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
10.07
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
2.90%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
6.00%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
2.28%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
4.14%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
7.70%
Dividend
Dividend Yield
Annual dividend divided by the current price: what percentage of your investment comes back as a payout each year.
2.83%
Dividend Per Share (TTM)
Sum of dividends paid per share over the last 12 months.
2.09$
Payout Ratio
Share of profit paid out as dividends. Over 100% means the company is paying out more than it earns — not sustainable long-term.
32.3%
Years Without a Cut
How many years in a row the dividend hasn't been cut — a measure of reliability.
12Years
Increase Streak
How many years in a row the dividend has been raised — the gold standard for dividend payers.
12Years
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
5
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
55
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (52 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
10.07
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.29 | 12.90 | 2,317 | 4.70 | 25.10 | 905 | 689 |
| 2025: Q1 | 1.41 | 7.90 | 2,220 | 1.40 | 28.40 | 587 | 438 |
| 2025: Q2 | 1.61 | 17.80 | 2,460 | 4.20 | 29.20 | 486 | 308 |
| 2025: Q3 | 1.63 | 8.20 | 2,400 | 0.50 | 30.00 | 938 | 805 |
| 2025: Q4 | 1.37 | 6.70 | 2,387 | 3.00 | 25.30 | 893 | 732 |
| 2026: Q1 | 1.42 | 1.00 | 2,262 | 1.90 | 26.60 | 401 | 291 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Zoetis Inc. entdeckt, entwickelt, fertigt und kommerzialisiert Medikamente, Impfstoffe, Diagnostikprodukte und -dienste, Biogeräte, Gentests und Präzisionslösungen für die Tiergesundheitsbranche in den USA und international.
| Employees | 14,500 |
|---|---|
| Headquarters | Parsippany, NJ |
| Website | zoetis.com |
| IPO Date | 1. Feb 2013 |
| Next Earnings | 6. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kristin C. Peck | CEO & Director | 1971 |
| Wetteny N. Joseph CPA | Executive VP & CFO | 1972 |
| Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 1965 |
| Robert J. Polzer Ph.D. | Scientific Advisor | 1969 |
| Jamie Brannan | Executive VP & Chief Commercial Officer | 1973 |
| Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 1979 |
| Steven Frank | Vice President of Investor Relations | – |
| Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 1973 |
| Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 1988 |
| Jeannette Ferran Astorga | Executive VP of Corporate Affairs & Chief Sustainability Officer | 1976 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.